Maud Toulmonde

B cells are associated with survival and immunotherapy response in sarcoma

Florent Petitprez, Aurélien de Reyniès, Emily Z. Keung et al. · Nature · 2020 · 1.9K citations · Full text

Medicine, Immunology, Oncology +17

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 614 citations

Medicine, Oncology, Pharmacology +12

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan et al. · Nature Cancer · 2021 · 569 citations · Full text

Life Sciences, Immunology, Oncology +17

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

Maud Toulmonde, Nicolas Penel, Julien Adam et al. · JAMA Oncology · 2017 · 394 citations · Full text

Medicine, Immunology, Oncology +17

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

Philippe A. Cassier, Antoîne Italiano, Carlos Gomez-Roca et al. · The Lancet Oncology · 2015 · 363 citations

Medicine, Oncology, Pharmacology +14